Foundation Medicine

Roche Diagnostics' revenues were driven by its centralized and point-of-care solutions as well as its tissue diagnostics business, both rising in the high-single digits.

The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.

An Oregon Health Authority committee issued a draft guidance to not cover NGS testing for solid tumors, which advocacy groups say will limit access to Medicaid beneficiaries.

The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.

The move is precipitated by CMS's decision to grant national coverage to NGS companion diagnostics when they're approved by the FDA.

The researchers distinguished histologic subtypes of appendiceal cancer and confirmed that it is distinct from colorectal and other GI cancers.

Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.

Under the terms of the settlement, the lawsuit, counterclaims, and challenges to the patent in inter partes review have been dismissed.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

Pages

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.